Search Results - "Burmester, Gerd"

Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Feb2026, Vol. 13 Issue 1, p293-297. 5p.

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Authors: Burmester, Gerd R. Stigler, Jayne Rubbert-Roth, Andrea et al.

Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p737-753. 17p.

Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Dec2023, Vol. 10 Issue 6, p1575-1595. 21p.

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Authors: Burmester, Gerd R. Coates, Laura C. Cohen, Stanley B. et al.

Source: Rheumatology & Therapy. Oct2023, Vol. 10 Issue 5, p1255-1276. 22p.

Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.

Authors: Burmester, Gerd Trefler, Jakub Racewicz, Artur et al.

Source: Clinical Drug Investigation. Aug2025, Vol. 45 Issue 8, p551-563. 13p.

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.

Authors: Alten, Rieke Burmester, Gerd R. Matucci-Cerinic, Marco et al.

Source: Rheumatology & Therapy. Feb2023, Vol. 10 Issue 1, p73-93. 21p.

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.

Authors: Burmester, Gerd R. Winthrop, Kevin Blanco, Ricardo et al.

Source: Rheumatology & Therapy. Apr2022, Vol. 9 Issue 2, p521-539. 19p.

A Randomized, Double‐Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.

Authors: Burmester, Gerd Chien, David Chow, Vincent et al.

Source: Clinical Pharmacology in Drug Development. Nov/Dec2020, Vol. 9 Issue 8, p1003-1014. 12p.

Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany.

Authors: Krüger, Klaus Burmester, Gerd Rüdiger Wassenberg, Siegfried et al.

Source: Rheumatology & Therapy. Jun2020, Vol. 7 Issue 2, p371-382. 12p.

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis.

Authors: Burmester, Gerd R. Coates, Laura C. Cohen, Stanley B. et al.

Source: Rheumatology & Therapy. Feb2024, Vol. 11 Issue 1, p221-222. 2p.

This result is not displayed to guests.
Login for full access.

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.

Authors: Burmester, Gerd R Strand, Vibeke Kivitz, Alan J et al.

Source: Rheumatology. Oct2023, Vol. 62 Issue 10, p3268-3279. 12p.

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis.

Authors: Burmester, Gerd R Bykerk, Vivian P Buch, Maya H et al.

Source: Rheumatology. Jun2022, Vol. 61 Issue 6, p2596-2602. 7p.

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.

Authors: Schnitzer TJ Burmester GR Mysler E et al.

Source: Lancet. 8/21/2004, Vol. 364 Issue 9435, p665-674. 10p.

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis.

Authors: Burmester, Gerd Drescher, Edit Hrycaj, Pawel et al.

Source: Clinical Rheumatology. Nov2020, Vol. 39 Issue 11, p3341-3352. 12p.

Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Authors: Krüger, Klaus Burmester, Gerd Rüdiger Wassenberg, Siegfried et al.

Source: Current Medical Research & Opinion. Sep2020, Vol. 36 Issue 9, p1559-1567. 9p.

Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.

Authors: Burmester, Gerd R Buttgereit, Frank Bernasconi, Corrado et al.

Source: Lancet. 7/25/2020, Vol. 396 Issue 10246, p267-276. 10p.

Subjects: Therapeutic use of glucocorticoids, Therapeutic use of monoclonal antibodies, Glucocorticoids, Research, Combination drug therapy, Intravenous therapy, Oral drug administration, Research methodology, Monoclonal antibodies, Evaluation research, Medical cooperation, Drug administration, Comparative studies, Randomized controlled trials, Severity of illness index, Rheumatoid arthritis, Blind experiment, Prednisone, Disease remission, Subcutaneous injections

Geographic Terms: Russia, Italy, France, Serbia, Tunisia, Germany

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.

Authors: Burmester, Gerd R. Curtis, Jeffrey R. Yun, Huifeng et al.

Source: Drug Safety. Apr2020, Vol. 43 Issue 4, p379-392. 14p.

Optimised glucocorticoid therapy: the sharpening of an old spear.

Authors: Buttgereit, Frank Burmester, Gerd-Rüdiger Lipworth, Brian J.

Source: Lancet. 2/26/2005, Vol. 365 Issue 9461, p801-803. 3p. 2 Diagrams.

Subjects: Glucocorticoids, Adrenocortical hormones, Anti-inflammatory agents, Drug side effects, Pediatric therapy

Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA).

Authors: Pongratz, Georg Alten, Rieke Witte, Torsten et al.

Source: Rheumatology & Therapy. Apr2026, Vol. 13 Issue 2, p435-449. 15p.